Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000950170-25-079298
Filing Date
2025-05-29
Accepted
2025-05-29 21:56:36
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 18500
2 EX-99.A ck0000000000-ex99_a.pdf EX-99.A 393871
  Complete submission text file 0000950170-25-079298.txt   562974
Mailing Address 3515 LYMAN BOULEVARD CHASKA MN 55318
Business Address 3515 LYMAN BOULEVARD CHASKA MN 55318 9523684300
LIFECORE BIOMEDICAL, INC. \DE\ (Subject) CIK: 0001005286 (see all company filings)

EIN.: 943025618 | State of Incorp.: DE | Fiscal Year End: 0525
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-45181 | Film No.: 251006080
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1455 NW LEARY WAY SUITE 400 SEATTLE WA 98107
Business Address 1455 NW LEARY WAY SUITE 400 SEATTLE WA 98107 206-227-3078
22NW Fund, LP (Filed by) CIK: 0001640809 (see all company filings)

EIN.: 473303449 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A